Acer Therapeutics — Opexa Therapeutics — Q1 2014 Earnings Presentation
7 slides from Acer Therapeutics's earnings presentation, May 14, 2014
Slide 1: Q1 2014 Earnings Call
May 14, 2014 Q1 2014 Earnings Call Opexa Therapeutics, Inc. Opexa Therapeutics, Inc. Precision Immunotherapy TM Precision Immunotherapy TM
Slide 2: Forward-Looking Statements
Forward-Looking Statements This earnings presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this r
Slide 3: Opexa's Mission
Opexa’s Mission To lead the field of Precision ImmunotherapyTM by aligning the interests of patients, employees and shareholders. 3
Slide 4: Abili-T: Phase IIb clinical trial Enrollment Target Reached
Abili-T : Phase IIb clinical trial Enrollment Target Reached FDA Fast Track Designation Secondary Progressive MS patients only Status –Enrolment target reached: 180 patients Patients currently in screening process still eligible to enroll Design –Double-blind, 1:1 randomized, placebo-controlled –Tri
Slide 5: Income Statement
5 Income Statement Q1 2014 Q1 2013 Option Revenue $0.35 MM $0.22 MM Research & Development $2.8 MM $1.6 MM General & Administrative $1.1 MM $1.1 MM Depreciation & Amortization $0.1 MM $0.1 MM Operating Loss $3.7 MM $2.6 MM Interest Expense - $1.6 MM Net Loss $3.7 MM $4.2 MM Basic and Diluted Loss pe
Slide 6: Balance Sheet Highlights
6 Balance Sheet Highlights Mar 31, 2014 Dec 31, 2013 Assets: Cash & Cash Equivalents $19.7 MM $23.6MM Prepaids & Other Current Assets $ 1.6 MM $ 1.1 MM Property Plant & Equipment $ 1.3 MM $ 1.3 MM Other Long Term Assets $ 0.2 MM $ 0.2 MM Liabilities & Shareholders’ Equity: Accounts Payable $ 0.7 MM
Slide 7: Investment Thesis
Investment Thesis T-cell platform company with Fast Track designation in SPMS Strong Intellectual property with 50 issued patents (domestic and international) Esteemed Scientific Advisory Board Precision Immunotherapy potentially optimizes benefit-risk profile Targeting an unmet medical need in a po